Introduction
============

Pancreatic pseudocysts (PP) are common local complications of pancreatitis that can be associated with significant morbidity [@JR1172-1] [@JR1172-2] . According to the revised Atlanta classification [@JR1172-3] , PP is defined as a mature fluid collection with a well-defined wall without solid components usually developing 4 weeks post-pancreatitis. Although generally asymptomatic and self-resolving, drainage of PP is required if there are persistent symptoms such as early satiety, abdominal pain, or gastric outlet obstruction despite adequate conservative management or when there is evidence of fluid collection infection [@JR1172-4] .

Endoscopic drainage with insertion of double pigtail plastic stents has been shown to be effective and safe and has gained popularity with the evolving field of therapeutic endoscopic ultrasound (EUS). Recently, lumen-apposing metal stents (LAMS) have been developed specifically for drainage of pancreatic fluid collections [@JR1172-5] . Advantages of LAMS include their large diameter (10 -- 15 mm), bi-flared flanges preventing stent migration, and ease of insertion as one-step devices including cautery without need for needle puncture, wire guidance, tract dilation, or fluoroscopic guidance. Prospective and retrospective series have shown excellent efficacy and safety of LAMS in management of PP [@JR1172-6] [@JR1172-7] [@JR1172-8] [@JR1172-9] [@JR1172-10] [@JR1172-11] [@JR1172-12] [@JR1172-13] [@JR1172-14] [@JR1172-15] ; however, LAMS are also known as considerably more expensive than traditional plastic stents (PS). Insertion of a stent could also generate possible adverse events and therefore the need for unplanned endoscopy, percutaneous drainage (PCD) or even surgery that should be taken into account in the comparison. There are currently no published cost-effectiveness data on use of LAMS in PP to inform optimal resource allocation. The objective of this work was to determine whether the advantages in terms of cost and effectiveness in favor of LAMS (reduced rate of complication) are outweighed by those in favor of PS (considering its success rate and lower stent price).

It is with this intricate backdrop in mind that this study aimed to assess the cost-effectiveness of EUS-guided drainage using LAMS (AXIOS, Boston Scientific, Marlborough, Massachusetts, United States) compared to PS in management of pancreatic pseudocysts.

Patients and methods
====================

Model design
------------

A decision model was constructed to assess clinical aspects of management of PP comparing LAMS to PS in inpatients over a 6-month period following stent insertion. This type of analysis was chosen to simultaneously evaluate cost and effectiveness of the traditional PS versus the novel LAMS. [Fig. 1](#FI1172-1){ref-type="fig"} shows that at the initial node, all inpatients receive a stent: either LAMS or PS. If this procedure fails, patients undergo PCD leading directly to a terminal node as a general assumption of the model is that any second modality used following initial drainage failure is successful. Otherwise, patients are followed for subsequent complication resulting in a need fir unplanned endoscopy, PCD or surgery. In the case of an unplanned endoscopy, a salvage plastic stent is assumed to be inserted in both LAMS and PS groups. Death as possible choice for unit of effectiveness was not considered in the model due to the lack of evidence to suggest differences in survival between PS and LAMS in the literature and the short but clinically appropriate chosen time horizon of 6 months [@JR1172-6] [@JR1172-8] [@JR1172-9] [@JR1172-10] [@JR1172-11] [@JR1172-12] [@JR1172-13] [@JR1172-14] [@JR1172-15] [@JR1172-16] . The unit of effectiveness was defined at the end of each path as the successful endoscopic drainage rate without need for PCD or surgery. The total cumulative representative costs across the time horizon were also computed for each path in the tree. This allows presentation of the outcome at each terminal node as the average individual total cost per patient drained successfully at the term of 6 months. Physician fees and hospital costs, including procedure costs and pharmaceutical costs, were considered in the context of a third-party-payer perspective. The software program TreeAge Pro Suite 2017 was used for this model and analysis [@OR1172-17] .

![ Model structure. Time horizon was 6 months. LAMS, lumen-apposing metal stent; PP, pancreatic pseudocyst; PS, plastic stent; PCD, percutaneous drain.](10-1055-a-0611-5082-i1172ei1){#FI1172-1}

Probabilities
-------------

### Search strategy

Probabilities were derived from the literature. A computerized medical literature search was performed using PubMed, the Cochrane library, and Embase from January 1992 until September 2016. Only fully published manuscripts in English were included. A highly sensitive search strategy was used to identify randomized, retrospective and prospective studies using the following keywords and MESH terms: pancreatitis, pancreatic pseudocyst, necrotizing pancreatitis, peripancreatic fluid collection, pancreatic fluid collection, acute necrotic collection, acute necrotizing collection, walled-off necrosis (WON), pancreatic abscess, pancreatic necrosis, EUS guided drainage, endoscopic ultrasound-guided drainage, endoscopic debridement, necrosectomy, endoscopic transmural drainage, sinus tract endoscopy, video-assisted retroperitoneal debridement, pseudocyst, percutaneous drainage. The search then focused on transmural drainage by using the keywords: 1) Transmural AND drainage (search all references), 2) EUS guided transmural drainage (search transmural drainage references) (Endoscopic; EUS; endoscopy) AND (ultrasound; ultrasonography), 3) Direct endoscopic necrosectomy (search all references), Endoscopic AND necrosectomy. In addition, recursive searches and cross-referencing were performed, as were hand searches of articles identified after the initial search was completed.

### Study selection and patient population

We included retrospective and prospective studies in English involving endoscopic drainage of pancreatic PP using LAMS (AXIOS LAMS Boston Scientific, Marlborough, Massachusetts, United States) or PS. Only fully published studies were included. Excluded articles were those that reported drainage of WON, review articles, articles with less than 10 cases, studies for which pseudocyst and pancreatic WON were not differentiated as per the Atlanta classification [@JR1172-3] , those addressing non EUS-guided endoscopic drainage, drainage performed with traditional esophageal or biliary metal stents, and drainage with SPAXUS or NAGI LAMS (Taewoong Medical, South Korea) [@OR1172-18] . All probabilities were calculated from a weighted average (per sample size) of the available literature.

### Study endpoints

Primary outcomes were technical and clinical success. Technical success was defined as successful stent insertion. Although successful drainage varied from study to study, we adopted a broad definition of symptomatic and radiographical resolution following stent insertion. Secondary outcomes included adverse events requiring unplanned endoscopic procedures, as well as the need for percutaneous drainage and surgery.

### Costs and lengths of stay

Costs for the analysis were calculated using billing claims at Johns Hopkins Hospital [@OR1172-19] . Inpatients who underwent endoscopic drainage or PCD of peripancreatic fluid collections between January 2012 and March 2016 were identified using procedure codes 0F9G4ZZ (drainage of pancreas, percutaneous endoscopic approach), 0F9G40Z (Drainage of pancreas with drain device, percutaneous endoscopic approach), and 5201 (drainage of pancreatic cyst by catheter). Overall and otherwise unselected, 12 patients who underwent drainage with a plastic stent, 14 patients with a LAMS, and four patients who underwent percutaneous drainage were identified. Mean charges for operating room (for index procedure, unplanned endoscopy, direct endoscopic necrosectomy), supply including stent prices, pharmacy, radiology, laboratory, therapy, other, and total were ascertained. Length of stay and associated charges were also obtained from the Johns Hopkins Hospital billing database; however, given the lack of patients who underwent surgery in our cohort, data on post-surgical LOS were obtained from the literature [@JR1172-20] . Charges were converted into costs using the Johns Hopkins Hospital's overall cost-to-charge ratio in the fiscal period when the procedure was performed. Indeed, we obtained cost-to-charge ratios from the Centers for Medicare and Medicaid Services [@OR1172-21] and Hospital Cost reports (HCR) [@OR1172-22] . Costs covered a period spanning 2012 to 2016; for procedures performed after July 1, 2015, the average charge-to-cost ratio across 2011 to 2014 was used. None of the 14 patients identified underwent surgical intervention. Therefore, institutional cost data were not available for surgical management of peripancreatic fluid collections. As such, estimates of surgical costs were ascertained using published literature, which also provided the physician fees for anesthesia [@JR1172-20] . All other professional/physician fees for endoscopic drainage, percutaneous drainage, and surgical cystgastrostomy were estimated using the average state fees of Maryland provided by the American Medical Association [@OR1172-23] . Hospital per diem costs were computed as the ratio of the cost per hospitalization to the associated LOS. Discounting was not applied due to the short time horizon. All costs were expressed in 2016 US dollars utilizing the consumer price index for the medical care services published by the United States Department of Labor [@OR1172-24] .

### Cost-effectiveness analysis

The effectiveness is expressed as the probability of successful endoscopic drainage without need for PCD or surgery over the full duration of the model. The costs are the sum of the cost items related to each event in the model. The outcome is the cost per patient drained successfully across the time horizon. Results are reported as cost, effectiveness, cost-effectiveness, and incremental cost effectiveness ratios.

### Sensitivity analyses

Both deterministic and probabilistic sensitivity analyses were undertaken. One-way sensitivity analyses on all variables of the models were done to assess robustness of the results. Sensitivity analyses allowed observation of how the results could change if the input variables included in the model were different than those chosen. We varied the value of each of the parameters of the model inside their respective pre-fixed ranges while other input variables were kept unchanged. Threshold analysis was also performed across plausible ranges on all variables to determine which variables could alter the conclusion. In addition, probabilistic sensitivity analysis was performed using a second-order Monte Carlo simulation running 10,000 variations of the model varying simultaneously all resampled parameters according to their statistical distributions [@BR1172-25] .

Cost-acceptability curve and incremental cost-effectiveness scatterplot (cloud diagram) were generated, adopting a willingness-to-pay threshold of US \$ 50,000 per successful outcome as we have done previously for such analyses [@JR1172-26] [@JR1172-27] . A willingness to pay (WTP) represents the pre-fixed maximum dollar value that is deemed as acceptable spending for a given treatment. It illustrates the probability that one type of stent is cost-effective compared the other one, given a WTP value.

The reporting of our results follows the Consolidated Health Economic Evaluation Reporting Standards Statement [@JR1172-28] .

Results
=======

Probability and cost assumptions
--------------------------------

A total of 5400 articles were identified and screened for potential inclusion. Following the removal of duplicates and the aforementioned exclusion criteria, 10 fully published manuscripts were included in the systematic review for the determination of probability assumptions ( [Appendix 1](#FI1172-4){ref-type="fig"} ) [@JR1172-6] [@JR1172-8] [@JR1172-9] [@JR1172-10] [@JR1172-11] [@JR1172-12] [@JR1172-13] [@JR1172-14] [@JR1172-15] [@JR1172-16] . These included nine retrospective studies and one prospective series. No randomized controlled trials were identified. There were a total of 51 patients in the LAMS cohort and 377 patients in PS group. Probabilities obtained from these studies are summarized in [Table 1](#TB1172-1){ref-type="table"} .

![](10-1055-a-0611-5082-i1172ei4){#FI1172-4}

###### Probabilities.

  **Description of probability**      **LAMS strategy**   **PS strategy**                                                                                      
  ----------------------------------- ------------------- ----------------- ------ ---------------------------------------------------- -------- ------ ------ -----------------------------------------------------------------------------------------
  Technical stent insertion success   0.9412              0.75              1      [@JR1172-6] [@JR1172-10] [@JR1172-14] [@JR1172-15]   0.9761   0.78   1      [@JR1172-6] [@JR1172-8] [@JR1172-9] [@JR1172-11] [@JR1172-12] [@JR1172-13] [@JR1172-16]
  Unplanned endoscopy                 0.1176              0.09              0.15   [@JR1172-6] [@JR1172-10] [@JR1172-14] [@JR1172-15]   0.1226   0.09   0.15   [@JR1172-6] [@JR1172-8] [@JR1172-9] [@JR1172-11] [@JR1172-12] [@JR1172-13] [@JR1172-16]
  PCD                                 0                   0                 0.05   [@JR1172-6] [@JR1172-10] [@JR1172-14] [@JR1172-15]   0.0068   0      0.05   [@JR1172-8] [@JR1172-9] [@JR1172-12] [@JR1172-13] [@JR1172-16]
  Surgery                             0.0196              0.01              0.05   [@JR1172-6] [@JR1172-10] [@JR1172-14] [@JR1172-15]   0.0473   0.03   0.06   [@JR1172-8] [@JR1172-9] [@JR1172-12] [@JR1172-13] [@JR1172-16]

LAMS, lumen-apposing metal stent; PCD, percutaneous drain; PS, plastic stent

All probabilities and their respective sources used in the model are listed in [Table 1](#TB1172-1){ref-type="table"} , while LOS and costs are shown in [Table 2](#TB1172-2){ref-type="table"} . The lower and upper limits of the intervals were set to ± 20 % of their respective baseline values for the probabilities and to ± 50 % for the costs. Probabilities followed beta and costs gamma distributions [@BR1172-29] .

###### Length of stay and costs.

  Category         Description                                               Baseline [1](#FN1172-1){ref-type="table-fn"}   Low [1](#FN1172-1){ref-type="table-fn"}   High [1](#FN1172-1){ref-type="table-fn"}   Source
  ---------------- --------------------------------------------------------- ---------------------------------------------- ----------------------------------------- ------------------------------------------ ----------------------------------------
  LOS              TIS/Unplanned endoscopy/PCD/Tn                               6                                              3                                         9                                       Billing claims [@OR1172-19]
  LOS              TIS/Unplanned endoscopy/surgery/Tn                          10                                              5                                        15                                       Billing claims [@OR1172-19]
  LOS              TIS/Unplanned endoscopy/Successfully drained patient/Tn      4                                              2                                         6                                       Billing claims [@OR1172-19]
  LOS              TIS/Successfully drained patient/Tn                          2                                             1                                         3                                        Billing claims [@OR1172-19]
  LOS              Technical failure at the insertion/PCD/Tn                    4                                              2                                         6                                       Billing claims [@OR1172-19]
  Per diem         Per diem hospital cost                                    2437                                           1218                                      3656                                       Billing claims [@OR1172-19]
  Price            PS                                                         104                                             52                                       156                                       Billing claims [@OR1172-19]
  Price            LAMS                                                      4930                                           2465                                      7395                                       Billing claims [@OR1172-19]
  Cost procedure   PS insertion                                              3272                                           1636                                      4908                                       Billing claims [@OR1172-19]
  Cost procedure   LAMS insertion                                            5237                                           2618                                      7856                                       Billing claims [@OR1172-19]
  Cost procedure   TIS/Unplanned endoscopy                                   3786                                           1893                                      5679                                       Billing claims [@OR1172-19]
  Cost procedure   Surgery                                                   2136                                           1068                                      3204                                       Varadarajulu [@JR1172-20] [@OR1172-24]
  Cost procedure   PCD                                                       3629                                           1814                                      5444                                       Billing claims [@OR1172-19]
  Physician fees   Stent insertion                                            443                                            221                                       665                                       CPT43240, [@OR1172-23]
  Physician fees   TIS/Unplanned endoscopy                                    203                                            101                                       305                                       CPT43247, [@OR1172-23]
  Physician fees   Surgery                                                   3154                                           1577                                      4731                                       CPT48105, [@OR1172-23]
  Physician fees   PCD                                                        231                                            115                                       347                                       CPT49406, [@OR1172-23]
  Physician fees   Anesthesia                                                 712                                            356                                      1068                                       Varadarajulu [@JR1172-20] [@OR1172-24]

LAMS, lumen-apposing metal stent; LOS, length-of-stay; PCD, percutaneous drain; PS, plastic stent; TIS, technical insertion success; Tn, terminal node

Costs are expressed in 2016 US \$ and LOS are expressed in days.

Base-case analysis
------------------

[Table 3](#TB1172-3){ref-type="table"} shows the overall cost-effectiveness analysis report according to the type of stent chosen to manage PP over 6 months. Inserting a LAMS would generate an average cost of US \$ 17,024 per patient in comparison with US \$ 10,087 for a PS. The success rate was 93.9 % for LAMS and 96.96 % for PS. Respective costs per successful drainage were US \$ 18,129 (LAMS) and US \$ 10,403 (PS). Being both more costly and less effective, the LAMS strategy was thus characterized as dominated (in the economic sense) by the PS approach.

###### Cost-effectiveness report.

  Strategy   Cost [1](#FN1172-2){ref-type="table-fn"}   IC     Effectiveness   IE          CER [1](#FN1172-2){ref-type="table-fn"}   
  ---------- ------------------------------------------ ------ --------------- ----------- ----------------------------------------- -----------
  PS         10 087                                            0.9696                      10 403                                    
  LAMS       17 024                                     6937   0.939           -- 0.0306   18 129                                    Dominated

Costs are expressed in 2016 US \$. Effectiveness is expressed as rate of successfully drained patient. CER, cost-effectiveness ratio; IC, incremental cost; CER, incremental cost-effectiveness ratio; IE, incremental effectiveness; LAMS, lumen-apposing metal stent; PS, plastic stent

Sensitivity analysis
--------------------

According to one-way sensitivity analysis, only the success rate of stent insertion could change the final preferred strategy. If the rate of success increased above 97.2 % for LAMS, or decreased below 94.5 % for PS, LAMS no longer dominated. The threshold analysis showed that other possible threshold values for changing the conclusions lie far outside the pre-set ranges of clinically relevant assumptions. This includes stent prices, which would not alter our conclusion even when the price of LAMS was varied from US \$ 0 to US \$ 20,000 while keeping the price of PS constant at US \$ 104. In addition, probabilities associated with the PS strategy of insertion success (more than 97 %), PCD (less than 1 %) or surgery (less than 5 %) should respectively decrease below 68 %, rise above 26 % and above 30 % for the LAMS strategy to no longer be dominated.

Probabilistic sensitivity analysis confirmed the robustness of the base case results. LAMS was dominated by PS in 74 % of simulation scenarios, while the LAMS approach preferred over PS in only 7.3 %. Overall, PS was chosen (more cost-effective or actually dominating LAMS) in 92.7 % of all simulations. [Fig. 2](#FI1172-2){ref-type="fig"} presents the incremental cost-effectiveness scatterplot with a WTP line drawn at US \$ 50,000: The point of origin (0;0) represents the PS strategy as reference. Each point of the cloud represents a difference between the PS and LAMS strategies from a point of view of both effectiveness and cost for every clinical scenario generated by the Monte Carlo Analysis. The ellipse that includes 95 % of all simulation points is to the left of the graph and slightly in the top quadrant, confirming that the LAMS strategy is most often less effective and more costly than the PS strategy using such a probabilistic assessment. The cost-acceptability curve ( [Fig. 3](#FI1172-3){ref-type="fig"} ) highlights how the value set for the WTP would not change the conclusion.

![ Incremental cost-effectiveness scatterplot LAMS versus PS. Costs are expressed in US \$. LAMS, lumen-apposing metal stent; PS, plastic stent; WTP, willingness to pay (Line displayed at US \$ 50,000.)](10-1055-a-0611-5082-i1172ei2){#FI1172-2}

![ Cost-effectiveness acceptability curve. LAMS, lumen-apposing metal stent; PS, plastic stent; WTP, willingness to pay expressed in US \$.](10-1055-a-0611-5082-i1172ei3){#FI1172-3}

Discussion
==========

Endoscopic-guided transmural drainage of pancreatic pseudocysts has gained popularity with the evolving field of therapeutic EUS. The advent of LAMS has created great excitement in this field with several studies demonstrating their excellent efficacy and safety in management of pancreatic fluid collections [@JR1172-6] [@JR1172-14] [@JR1172-30] [@JR1172-31] . The major disadvantage associated with LAMS are their high cost. To our knowledge, this is the first cost-effectiveness analysis comparing LAMS with PS in management of PP, which is timely given that many endoscopy centers worldwide are contemplating adopting these devices. Our results would be generalizable for countries with similar proportional cost structure with cost estimates falling within our ranges.

In this study, use of LAMS appeared to be dominated by PS in management of pancreatic pseudocysts meaning that use of LAMS is not more beneficial while being costlier than PS. These results are robust and are consistent throughout extensive deterministic and probabilistic sensitivity analyses, meaning that our conclusion does not alter despite considering large variations in probability and costs assumptions.

Favorable stent characteristics of LAMS including their larger luminal diameter and bi-flared flanges preventing stent migration do not appear to provide significant incremental benefits over PS in PP -- probably given the absence of solid debris and therefore low likelihood of plastic stent obstruction. The same could not be said of pancreatic WON, defined as a mature pancreatic collection with solid debris, where risk for stent obstruction is high and where a larger stent diameter along with anti-migration properties to allow for direct endoscopic necrosectomy through the stent provide significant additional improvements in outcome. Indeed, retrospective comparative studies have suggested that LAMS may be more effective than PS in WON [@JR1172-32] . As a result, it is not surprising that a recent cost analysis, by our group, suggested LAMS are cost-effective when compared to PS in the endoscopic drainage of WON [@JR1172-33] . Overall, our data reaffirm the need for proper diagnosis and classification of pancreatic fluid collections to select the most appropriate management approach. For optimal resource allocation, it appears that LAMS are best reserved for WON while the use of PS is likely the better choice in pancreatic pseudocysts. Many endoscopists nevertheless will likely opt for use of LAMS over PS in PP given their ease of insertion, especially in community hospitals where fluoroscopy access may be limited. However, in tertiary centers where endoscopic expertise is available and where fluoroscopic assistance is readily accessible, PS is likely the better and more cost-effective modality for PP.

There are several important aspects of our study that merit further discussion. First, we did not use Quality Adjusted Life Years (QALYs) as the measure of effectiveness as for acute medical conditions such as pancreatic pseudocysts, better adapted clinical endpoints including successful endoscopic drainage may be a more appropriate alternative to optimally inform resource allocation [@JR1172-34] [@JR1172-35] . In addition, death was not included in the analysis given its low prevalence in this patient population, lack of data to suggest any differences between the two groups in the literature, [@JR1172-6] [@JR1172-8] [@JR1172-9] [@JR1172-10] [@JR1172-11] [@JR1172-12] [@JR1172-13] [@JR1172-14] [@JR1172-15] [@JR1172-16] , and the adopted short study time-horizon, as similarly justified in past cost-effectiveness models addressing endoscopic hemostasis [@JR1172-26] . In clinical practice the majority of pseudocyst recurrence occurs within a few months following clinical success. Considering that the most relevant direct and measurable consequences occur in the first months following insertion and considering the lack of long-term data in the literature, a time horizon of 6 months was adopted. Limitations of the study include the fact that the decision tree may be oversimplified, although it was constructed in a manner to be as comprehensive as possible and clinically relevant, with the literature informing the different assumptions chosen for the health states. Also, only inpatient costs were included to have a more homogenous patient population with more conservative assumptions; however, this may limit the generalizability of results to outpatients. In terms of probability assumptions, there were no controlled trials available in the literature and data were obtained from retrospective and prospective series, which likely led to an overestimation of technical and clinical success with both LAMS and PS. Inherent biases in these studies may also explain the surprising finding that PS was slightly more effective than LAMS. In our sensitivity analysis, however, LAMS would only no longer be dominated if drainage success, need for PCD, and need for surgery with PS should respectively decrease below 68 %, rise above 26 %, and above 30 %. As such, biases in the literature are unlikely to affect our results, which appear to be robust. As for costs, the generalizability of the chosen estimates may be limited as only a single institution was used for source data while only the Maryland AMA information was used for professional fees. An exploratory analysis we carried out (data available upon request) suggest that using the national US average would have given a maximal variation of 10 % of the values we used for Maryland. These variations were thus included in the ranges we used for the sensitivity analysis. Similarly, cost data for surgical intervention were obtained from the literature as no institutional data were available [@JR1172-20] . Lastly the analysis did not include use of traditional fully-covered metal biliary or esophageal stents as well as other LAMS such as the NAGI or SPAXUS stents. Considering the wide ranges of assumptions used for sensitivity analysis of all cost data, as shown in [Table 2](#TB1172-2){ref-type="table"} , these limitations were thus once again likely accounted for and do not change our conclusions.

Conclusion
==========

In conclusion, use of PS is more effective than LAMS while being also less costly in management of pancreatic pseudocysts. As such, PS should be preferred over LAMS as initial management of patients with PP.
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